DC-S239

• UNSPSC Description:

  DC-S239 is a selective histone methyltransferase SET7 inhibitor with an IC50 value of 4.59 μM. DC-S239 also displays selectivity for DNMT1, DOT1L, EZH2, NSD1, SETD8 and G9a. DC-S239 has anticancer activity[1].

• Target Antigen:

  Histone Methyltransferase

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/dc-s239.html

• Purity:

  99.43

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  O=C(OCC)C1=C(SC(C(NC2=CC=CC([N+]([O-])=O)=C2)=O)=C1C)N

• Molecular Weight:

  349.36

• References & Citations:

  [1]Fanwang Meng, et al. Discovery and Optimization of Novel, Selective Histone Methyltransferase SET7 Inhibitors by Pharmacophore- and Docking-Based Virtual Screening. J Med Chem. 2015 Oct 22;58(20):8166-81.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  303141-21-1